517920-70-6 Usage
Uses
Used in Organic Synthesis:
2-Fluoro-4-Bromo-6-Nitroaniline is used as a key intermediate in organic synthesis for the production of a wide range of chemical compounds. Its unique structure, featuring fluorine and bromine atoms, allows for various chemical reactions, making it a valuable building block in the synthesis of complex organic molecules.
Used in Dye and Pigment Production:
In the dye and pigment industry, 2-Fluoro-4-Bromo-6-Nitroaniline is utilized as a starting material for the synthesis of various dyes and pigments. Its ability to undergo different chemical reactions enables the creation of a diverse range of colorants with specific properties, such as color intensity, stability, and solubility.
Used in Pharmaceutical Industry:
2-Fluoro-4-Bromo-6-Nitroaniline is employed as an intermediate in the synthesis of pharmaceutical compounds. Its unique structure and reactivity make it suitable for the development of new drugs with potential therapeutic applications. The presence of fluorine and bromine atoms in its structure can influence the pharmacokinetic and pharmacodynamic properties of the resulting pharmaceuticals, potentially enhancing their efficacy and safety.
Check Digit Verification of cas no
The CAS Registry Mumber 517920-70-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,7,9,2 and 0 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 517920-70:
(8*5)+(7*1)+(6*7)+(5*9)+(4*2)+(3*0)+(2*7)+(1*0)=156
156 % 10 = 6
So 517920-70-6 is a valid CAS Registry Number.
InChI:InChI=1/C6H4BrFN2O2/c7-3-1-4(8)6(9)5(2-3)10(11)12/h1-2H,9H2
517920-70-6Relevant articles and documents
TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
-
, (2018/03/25)
Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
